Edition:
United Kingdom

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.87USD
15 Dec 2017
Change (% chg)

$-0.08 (-4.10%)
Prev Close
$1.95
Open
$1.95
Day's High
$1.97
Day's Low
$1.84
Volume
3,436,152
Avg. Vol
438,388
52-wk High
$2.87
52-wk Low
$1.30

Select another date:

Wed, Nov 29 2017

BRIEF-U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals presents positive translational and clinical data update from ongoing IMO-2125 development program

* Idera Pharmaceuticals Inc presents positive translational and clinical data update from ongoing IMO-2125 development program at the 2017 society for immunotherapy of cancer annual meeting (SITC)

BRIEF-Idera Pharmaceuticals reports Q3 loss per share $0.10

* Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Idera Pharma announces pricing of public offering of common stock

* Idera Pharmaceuticals announces pricing of public offering of common stock

BRIEF-Idera Pharmaceuticals provides corporate governance update

* Idera Pharmaceuticals provides corporate governance update Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals announces proposed public offering of common stock

* Idera Pharmaceuticals announces proposed public offering of common stock

BRIEF-Idera Pharmaceuticals files for‍​ mixed shelf

* Idera pharmaceuticals inc files for‍​ mixed shelf of up to $250 million - sec filing‍​ Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals Q2 loss per share $0.14

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

BRIEF-FDA gives "orphan drug" status to Idera's skin cancer drug

* Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma

Select another date: